He is the co-founder and CEO of Omniox, bringing his scientific expertise and leadership skills to drive the company's success. With a background in biotechnology and a PhD in Chemistry, Jonathan is committed to developing innovative oxygen-based therapies to address unmet medical needs. Under his guidance, Omniox has assembled a team of experienced scientific and biotechnology professionals who share a passion for making a difference in patients' lives.

The company's advisory boards consist of world-leading experts in medicine, science, and business, ensuring that their research and development efforts are guided by the best in the field. Omniox's core technology, the H-NOX platform, is a breakthrough in oxygen delivery. By leveraging this technology, they are developing first-in-class and best-in-class OMX oxygen delivery vehicles.

These vehicles have the potential to treat a wide range of medical conditions where tissue hypoxia plays a role in disease progression. The company has received grants and funding from prestigious sources such as the National Cancer Institute, National Institute of Neurological Disorders and Stroke, the Wellcome Trust, and private investors. This support further validates the potential of Omniox's innovative approach.

Driven by their mission to solve clinical problems where hypoxia is central, Omniox operates with values of scientific and operational excellence. Their teams are passionate, versatile, and exceptional, ensuring that they tackle challenges with transparency and diligence. They approach difficult problems with an open-minded and courageous mindset, committed to successful outcomes.

Omniox's vision is to pioneer innovative oxygen-based therapies that restore health to patients. Through their proprietary oxygen-delivery platform and strong partnerships, they aim to provide meaningful therapeutic benefits to those in need. With their unwavering commitment to science and patient-centric approach, Omniox is poised to revolutionize the field of biotechnology and improve patient outcomes